Adrenomedullin as a therapeutic target in angiogenesis

Bibliography

• Kitamura K, Kangawa K, Kawamoto M, Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993;192(2):553-60
   PubMed Web of Science ®Google Scholar
• Kitamura K, Sakata J, Kangawa K, Cloning and characterization of cDNA encoding a precursor for human adrenomedullin. Biochem Biophys Res Commun 1993;194(2):720-5
   PubMed Web of Science ®Google Scholar
• Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 2000;21(2):138-67
   PubMed Web of Science ®Google Scholar
• Eguchi S, Hirata Y, Iwasaki H, Structure–activity relationship of adrenomedullin, a novel vasodilatory peptide, in cultured rat vascular smooth muscle cells. Endocrinology 1994;135(6):2454-8
   PubMed Web of Science ®Google Scholar
• Merkler DJ. C-terminal amidated peptides: production by the in vitro enzymatic amidation of glycine-extended peptides and the importance of the amide to bioactivity. Enzyme Microb Technol 1994;16(6):450-6
   PubMed Web of Science ®Google Scholar
• Caron KM, Smithies O. Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional adrenomedullin gene. Proc Natl Acad Sci USA 2001;98(2):615-19
   PubMed Web of Science ®Google Scholar
• Kapas S, Catt KJ, Clark AJ. Cloning and expression of cDNA encoding a rat adrenomedullin receptor. J Biol Chem 1995;270(43):25344-7
   PubMed Web of Science ®Google Scholar
• McLatchie LM, Fraser NJ, Main MJ, RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998;393(6683):333-9
   PubMed Web of Science ®Google Scholar
• Njuki F, Nicholl CG, Howard A, A new calcitonin-receptor-like sequence in rat pulmonary blood vessels. Clin Sci (Lond) 1993;85(4):385-8
   PubMed Web of Science ®Google Scholar
• Sakata J, Shimokubo T, Kitamura K, Distribution and characterization of immunoreactive rat adrenomedullin in tissue and plasma. FEBS Lett 1994;352(2):105-8
   PubMed Web of Science ®Google Scholar
• Ishiyama Y, Kitamura K, Ichiki Y, Hemodynamic effects of a novel hypotensive peptide, human adrenomedullin, in rats. Eur J Pharmacol 1993;241(2-3):271-3
   PubMed Web of Science ®Google Scholar
• Rademaker MT, Charles CJ, Lewis LK, Beneficial hemodynamic and renal effects of adrenomedullin in an ovine model of heart failure. Circulation 1997;96(6):1983-90
   PubMed Web of Science ®Google Scholar
• Ishimitsu T, Nishikimi T, Saito Y, Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1994;94(5):2158-61
   PubMed Web of Science ®Google Scholar
• Sumimoto T, Nishikimi T, Mukai M, Plasma adrenomedullin concentrations and cardiac and arterial hypertrophy in hypertension. Hypertension 1997;30(3 Pt 2):741-5
   PubMed Web of Science ®Google Scholar
• Jougasaki M, Wei CM, McKinley LJ, Burnett Jr JC. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation 1995;92(3):286-9
   PubMed Web of Science ®Google Scholar
• Nishikimi T, Saito Y, Kitamura K, Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol 1995;26(6):1424-31
   PubMed Web of Science ®Google Scholar
• Nishikimi T, Nagata S, Sasaki T, Plasma concentrations of adrenomedullin correlate with the extent of pulmonary hypertension in patients with mitral stenosis. Heart 1997;78(4):390-5
   PubMed Web of Science ®Google Scholar
• Yoshibayashi M, Kamiya T, Kitamura K, Plasma levels of adrenomedullin in primary and secondary pulmonary hypertension in patients <20 years of age. Am J Cardiol 1997;79(11):1556-8
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Kitamura K, Hirayama N, Increased plasma adrenomedullin in acute myocardial infarction. Am Heart J 1996;131(4):676-80
   PubMed Web of Science ®Google Scholar
• Miyao Y, Nishikimi T, Goto Y, Increased plasma adrenomedullin levels in patients with acute myocardial infarction in proportion to the clinical severity. Heart 1998;79(1):39-44
   PubMed Web of Science ®Google Scholar
• Hippenstiel S, Witzenrath M, Schmeck B, Adrenomedullin reduces endothelial hyperpermeability. Circ Res 2002;91(7):618-25
   PubMed Web of Science ®Google Scholar
• Abe M, Sata M, Suzuki E, Effects of adrenomedullin on acute ischaemia-induced collateral development and mobilization of bone-marrow-derived cells. Clin Sci (Lond) 2006;111(6):381-7
   PubMed Web of Science ®Google Scholar
• Iwase T, Nagaya N, Fujii T, Adrenomedullin enhances angiogenic potency of bone marrow transplantation in a rat model of hindlimb ischemia. Circulation 2005;111(3):356-62
   PubMed Web of Science ®Google Scholar
• Kong XQ, Wang LX, Yang CS, Effects of adrenomedullin on the cell numbers and apoptosis of endothelial progenitor cells. Clin Invest Med 2008;31(3):E117-22
   Web of Science ®Google Scholar
• Martinez A, Zudaire E, Portal-Nunez S, Proadrenomedullin NH2-terminal 20 peptide is a potent angiogenic factor, and its inhibition results in reduction of tumor growth. Cancer Res 2004;64(18):6489-94
   PubMed Web of Science ®Google Scholar
• Nikitenko LL, Fox SB, Kehoe S, Adrenomedullin and tumour angiogenesis. Br J Cancer 2006;94(1):1-7
   PubMed Web of Science ®Google Scholar
• Miller MJ, Martinez A, Unsworth EJ, Adrenomedullin expression in human tumor cell lines. Its potential role as an autocrine growth factor. J Biol Chem 1996;271(38):23345-51
   PubMed Web of Science ®Google Scholar
• Ouafik L, Sauze S, Boudouresque F, Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo. Am J Pathol 2002;160(4):1279-92
   PubMed Web of Science ®Google Scholar
• Deville JL, Bartoli C, Berenguer C, Expression and role of adrenomedullin in renal tumors and value of its mRNA levels as prognostic factor in clear-cell renal carcinoma. Int J Cancer 2009;125(10):2307-15
   PubMed Web of Science ®Google Scholar
• Rocchi P, Boudouresque F, Zamora AJ, Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines. Cancer Res 2001;61(3):1196-206
   PubMed Web of Science ®Google Scholar
• Ramachandran V, Arumugam T, Hwang RF, Adrenomedullin is expressed in pancreatic cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor, ADMR. Cancer Res 2007;67(6):2666-75
   PubMed Web of Science ®Google Scholar
• Keleg S, Kayed H, Jiang X, Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion. Int J Cancer 2007;121(1):21-32
   PubMed Web of Science ®Google Scholar
• Oehler MK, Fischer DC, Orlowska-Volk M, Tissue and plasma expression of the angiogenic peptide adrenomedullin in breast cancer. Br J Cancer 2003;89(10):1927-33
   PubMed Web of Science ®Google Scholar
• Buyukberber S, Sari I, Camci C, Adrenomedullin expression does not correlate with survival in lung cancer. Med Oncol 2007;24(2):245-9
   PubMed Web of Science ®Google Scholar
• Liu J, Butzow R, Hyden-Granskog C, Voutilainen R. Expression of adrenomedullin in human ovaries, ovarian sex cord-stromal tumors and cultured granulosa-luteal cells. Gynecol Endocrinol 2009;25(2):96-103
   PubMed Web of Science ®Google Scholar
• Takahashi K, Satoh F, Sone M, Expression of adrenomedullin mRNA in adrenocortical tumors and secretion of adrenomedullin by cultured adrenocortical carcinoma cells. Peptides 1998;19(10):1719-24
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yoshinoya A, Murakami O, Production and secretion of two vasoactive peptides, adrenomedullin and endothelin-1, by cultured human adrenocortical carcinoma cells. Peptides 2000;21(2):251-6
   PubMed Web of Science ®Google Scholar
• Michelsen J, Thiesson H, Walter S, Tissue expression and plasma levels of adrenomedullin in renal cancer patients. Clin Sci (Lond) 2006;111(1):61-70
   PubMed Web of Science ®Google Scholar
• Ehlenz K, Koch B, Preuss P, High levels of circulating adrenomedullin in severe illness: correlation with C-reactive protein and evidence against the adrenal medulla as site of origin. Exp Clin Endocrinol Diabetes 1997;105(3):156-62
   PubMed Web of Science ®Google Scholar
• Letizia C, Di Iorio R, De Toma G, Circulating adrenomedullin is increased in patients with corticotropin-dependent Cushing's syndrome due to pituitary adenoma. Metabolism 2000;49(6):760-3
   PubMed Web of Science ®Google Scholar
• Dupuis J, Caron A, Ruel N. Biodistribution, plasma kinetics and quantification of single-pass pulmonary clearance of adrenomedullin. Clin Sci (Lond) 2005;109(1):97-102
   PubMed Web of Science ®Google Scholar
• Pio R, Martinez A, Unsworth EJ, Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. J Biol Chem 2001;276(15):12292-300
   PubMed Web of Science ®Google Scholar
• Martinez A, Oh HR, Unsworth EJ, Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J 2004;383(Pt 3):413-18
   PubMedGoogle Scholar
• Harris AL. Hypoxia – a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2(1):38-47
   PubMed Web of Science ®Google Scholar
• Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3(10):721-32
   PubMed Web of Science ®Google Scholar
• Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998;95(14):7987-92
   PubMed Web of Science ®Google Scholar
• Salceda S, Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997;272(36):22642-7
   PubMed Web of Science ®Google Scholar
• Maxwell PH, Wiesener MS, Chang GW, The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399(6733):271-5
   PubMed Web of Science ®Google Scholar
• Foster K, Prowse A, van den Berg A, Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994;3(12):2169-73
   PubMed Web of Science ®Google Scholar
• Gnarra JR, Tory K, Weng Y, Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7(1):85-90
   PubMed Web of Science ®Google Scholar
• Herman JG, Latif F, Weng Y, Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;91(21):9700-4
   PubMed Web of Science ®Google Scholar
• Wiesener MS, Munchenhagen PM, Berger I, Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 2001;61(13):5215-22
   PubMed Web of Science ®Google Scholar
• Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22(24):4991-5004
   PubMed Web of Science ®Google Scholar
• Kuwai T, Kitadai Y, Tanaka S, Mutation of the von Hippel-Lindau (VHL) gene in human colorectal carcinoma: association with cytoplasmic accumulation of hypoxia-inducible factor (HIF)-1alpha. Cancer Sci 2004;95(2):149-53
   PubMed Web of Science ®Google Scholar
• Garayoa M, Martinez A, Lee S, Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol 2000;14(6):848-62
   PubMedGoogle Scholar
• Nguyen SV, Claycomb WC. Hypoxia regulates the expression of the adrenomedullin and HIF-1 genes in cultured HL-1 cardiomyocytes. Biochem Biophys Res Commun 1999;265(2):382-6
   PubMed Web of Science ®Google Scholar
• Ogita T, Hashimoto E, Yamasaki M, Hypoxic induction of adrenomedullin in cultured human umbilical vein endothelial cells. J Hypertens 2001;19(3 Pt 2):603-8
   PubMed Web of Science ®Google Scholar
• Beyer S, Kristensen MM, Jensen KS, The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J Biol Chem 2008;283(52):36542-52
   PubMed Web of Science ®Google Scholar
• Pollard PJ, Loenarz C, Mole DR, Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha. Biochem J 2008;416(3):387-94
   PubMedGoogle Scholar
• Wellmann S, Bettkober M, Zelmer A, Hypoxia upregulates the histone demethylase JMJD1A via HIF-1. Biochem Biophys Res Commun 2008;372(4):892-7
   PubMed Web of Science ®Google Scholar
• Krieg AJ, Rankin EB, Chan D, Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Mol Cell Biol 2010;30(1):344-53
   PubMed Web of Science ®Google Scholar
• Michiels C, Minet E, Michel G, HIF-1 and AP-1 cooperate to increase gene expression in hypoxia: role of MAP kinases. IUBMP Life 2001;52(1-2):49-53
   PubMed Web of Science ®Google Scholar
• Minet E, Arnould T, Michel G, ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett 2000;468(1):53-8
   PubMed Web of Science ®Google Scholar
• Zhou J, Fandrey J, Schumann J, NO and TNF- released from activated macrophages stabilize HIF-1 in resting tubular LLC-PK1 cells. Am J Physiol Cell Physiol 2003;284(2):C439-46
   Web of Science ®Google Scholar
• Jung YJ, Isaacs JS, Lee S, IL-1beta-mediated up-regulation of HIF-1alpha via an NFKappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 2003;17(14):2115-17
   PubMedGoogle Scholar
• Horio T, Nishikimi T, Yoshihara F, Production and secretion of adrenomedullin in cultured rat cardiac myocytes and nonmyocytes: stimulation by interleukin-1beta and tumor necrosis factor-alpha. Endocrinology 1998;139(11):4576-80
   PubMed Web of Science ®Google Scholar
• Sugo S, Minamino N, Shoji H, Interleukin-1, tumor necrosis factor and lipopolysaccharide additively stimulate production of adrenomedullin in vascular smooth muscle cells. Biochem Biophys Res Commun 1995;207(1):25-32
   PubMed Web of Science ®Google Scholar
• Takahashi K, Nakayama M, Totsune K, Increased secretion of adrenomedullin from cultured human astrocytes by cytokines. J Neurochem 2000;74(1):99-103
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rey E, Chorny A, O'Valle F, Delgado M. Adrenomedullin protects from experimental arthritis by down-regulating inflammation and Th1 response and inducing regulatory T cells. Am J Pathol 2007;170(1):263-71
   PubMed Web of Science ®Google Scholar
• Miksa M, Wu R, Cui X, Vasoactive hormone adrenomedullin and its binding protein: anti-inflammatory effects by up-regulating peroxisome proliferator-activated receptor-gamma. J Immunol 2007;179(9):6263-72
   PubMed Web of Science ®Google Scholar
• Ueda S, Nishio K, Minamino N, Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome. Am J Respir Crit Care Med 1999;160(1):132-6
   PubMed Web of Science ®Google Scholar
• Wong LY, Cheung BM, Li YY, Tang F. Adrenomedullin is both proinflammatory and antiinflammatory: its effects on gene expression and secretion of cytokines and macrophage migration inhibitory factor in NR8383 macrophage cell line. Endocrinology 2005;146(3):1321-7
   PubMed Web of Science ®Google Scholar
• Yang S, Zhou M, Fowler DE, Wang P. Mechanisms of the beneficial effect of adrenomedullin and adrenomedullin-binding protein-1 in sepsis: down-regulation of proinflammatory cytokines. Crit Care Med 2002;30(12):2729-35
   PubMed Web of Science ®Google Scholar
• O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001;85(4):473-83
   PubMed Web of Science ®Google Scholar
• Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology (Williston Park) 2002;16(2):217-26, 29; discussion 30-2
   PubMed Web of Science ®Google Scholar
• Ishimitsu T, Kojima M, Kangawa K, Genomic structure of human adrenomedullin gene. Biochem Biophys Res Commun 1994;203(1):631-9
   PubMed Web of Science ®Google Scholar
• Imagawa M, Chiu R, Karin M. Transcription factor AP-2 mediates induction by two different signal-transduction pathways: protein kinase C and cAMP. Cell 1987;51(2):251-60
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang S, Shang H, Basic fibroblast growth factor upregulates adrenomedullin expression in ovarian epithelial carcinoma cells via JNK-AP-1 pathway. Regul Pept 2009;157(1-3):44-50
   PubMedGoogle Scholar
• Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8(4):299-309
   PubMed Web of Science ®Google Scholar
• Pearson LJ, Yandle TG, Nicholls MG, Evans JJ. Regulation of endothelin-1 release from human endothelial cells by sex steroids and angiotensin-II. Peptides 2008;29(6):1057-61
   PubMed Web of Science ®Google Scholar
• Evans JJ, Youssef AH, Yandle TG, Effects of endothelin-1 on release of adrenomedullin and C-type natriuretic peptide from individual human vascular endothelial cells. J Endocrinol 2002;175(1):225-32
   PubMed Web of Science ®Google Scholar
• Dhaun N, Macintyre IM, Melville V, Effects of endothelin receptor antagonism relate to the degree of renin-angiotensin system blockade in chronic proteinuric kidney disease. Hypertension 2009;54(3):e19-20
   PubMed Web of Science ®Google Scholar
• Dhaun N, Macintyre IM, Melville V, Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 2009;54(1):113-19
   PubMed Web of Science ®Google Scholar
• Goddard J, Johnston NR, Hand MF, Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004;109(9):1186-93
   PubMed Web of Science ®Google Scholar
• Zudaire E, Cuttitta F, Martinez A. Regulation of pancreatic physiology by adrenomedullin and its binding protein. Regul Pept 2003;112(1-3):121-30
   PubMedGoogle Scholar
• Patard JJ, Kim HL, Lam JS, Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004;22(16):3316-22
   PubMed Web of Science ®Google Scholar
• Zisman A, Pantuck AJ, Dorey F, Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001;19(6):1649-57
   PubMed Web of Science ®Google Scholar
• Park SC, Yoon JH, Lee JH, Hypoxia-inducible adrenomedullin accelerates hepatocellular carcinoma cell growth. Cancer Lett 2008;271(2):314-22
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hoppe S, Papadopoulos T, Adrenomedullin is a novel marker of tumor progression in neuroendocrine carcinomas. Horm Metab Res 2006;38(2):112-18
   PubMed Web of Science ®Google Scholar
• Berenguer C, Boudouresque F, Dussert C, Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates ‘neuroendocrine phenotype’ in LNCaP prostate tumor cells. Oncogene 2008;27(4):506-18
   PubMed Web of Science ®Google Scholar
• Krijnen JL, Bogdanowicz JF, Seldenrijk CA, The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 1997;158(1):171-4
   PubMed Web of Science ®Google Scholar
• Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 1997;79(7):1370-80
   PubMed Web of Science ®Google Scholar
• Hata K, Takebayashi Y, Akiba S, Expression of the adrenomedullin gene in epithelial ovarian cancer. Mol Hum Reprod 2000;6(10):867-72
   PubMed Web of Science ®Google Scholar
• Dotsch J, Harmjanz A, Christiansen H, Gene expression of neuronal nitric oxide synthase and adrenomedullin in human neuroblastoma using real-time PCR. Int J Cancer 2000;88(2):172-5
   PubMed Web of Science ®Google Scholar
• Oehler MK, Norbury C, Hague S, Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: a possible promotion mechanism for tumour growth. Oncogene 2001;20(23):2937-45
   PubMed Web of Science ®Google Scholar
• Nunobiki O, Nakamura M, Taniguchi E, Adrenomedullin, Bcl-2 and microvessel density in normal, hyperplastic and neoplastic endometrium. Pathol Int 2009;59(8):530-6
   PubMed Web of Science ®Google Scholar
• Oehler MK, Hague S, Rees MC, Bicknell R. Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis. Oncogene 2002;21(18):2815-21
   PubMed Web of Science ®Google Scholar
• Martinez A, Vos M, Guedez L, The effects of adrenomedullin overexpression in breast tumor cells. J Natl Cancer Inst 2002;94(16):1226-37
   PubMedGoogle Scholar
• Ishikawa T, Chen J, Wang J, Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis. Oncogene 2003;22(8):1238-42
   PubMed Web of Science ®Google Scholar
• Ajona D, Castano Z, Garayoa M, Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res 2004;64(17):6310-18
   PubMed Web of Science ®Google Scholar
• Gasque P, Julen N, Ischenko AM, Expression of complement components of the alternative pathway by glioma cell lines. J Immunol 1992;149(4):1381-7
   PubMed Web of Science ®Google Scholar
• Gasque P, Thomas A, Fontaine M, Morgan BP. Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins. J Neuroimmunol 1996;66(1-2):29-40
   PubMed Web of Science ®Google Scholar
• Junnikkala S, Hakulinen J, Jarva H, Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br J Cancer 2002;87(10):1119-27
   PubMed Web of Science ®Google Scholar
• Kinders R, Jones T, Root R, Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res 1998;4(10):2511-20
   PubMed Web of Science ®Google Scholar
• Legoedec J, Gasque P, Jeanne JF, Fontaine M. Expression of the complement alternative pathway by human myoblasts in vitro: biosynthesis of C3, factor B, factor H and factor I. Eur J Immunol 1995;25(12):3460-6
   PubMed Web of Science ®Google Scholar
• Zudaire E, Martínez A, Garayoa M, Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis. Am J Pathol 2006;168(1):280-91
   PubMed Web of Science ®Google Scholar
• Guidolin D, Albertin G, Spinazzi R, Adrenomedullin stimulates angiogenic response in cultured human vascular endothelial cells: involvement of the vascular endothelial growth factor receptor 2. Peptides 2008;29(11):2013-23
   PubMed Web of Science ®Google Scholar
• Levine L, Lucci III JA, Pazdrak B, Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 2003;63(13):3495-502
   PubMed Web of Science ®Google Scholar
• Nikitenko LL, MacKenzie IZ, Rees MC, Bicknell R. Adrenomedullin is an autocrine regulator of endothelial growth in human endometrium. Mol Hum Reprod 2000;6(9):811-19
   PubMed Web of Science ®Google Scholar
• Kato H, Shichiri M, Marumo F, Hirata Y. Adrenomedullin as an autocrine/paracrine apoptosis survival factor for rat endothelial cells. Endocrinology 1997;138(6):2615-20
   PubMed Web of Science ®Google Scholar
• Shindo T, Kurihara Y, Nishimatsu H, Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene. Circulation 2001;104(16):1964-71
   PubMed Web of Science ®Google Scholar
• Fritz-Six KL, Dunworth WP, Li M, Caron KM. Adrenomedullin signaling is necessary for murine lymphatic vascular development. J Clin Invest 2008;118(1):40-50
   PubMed Web of Science ®Google Scholar
• Ichikawa-Shindo Y, Sakurai T, Kamiyoshi A, The GPCR modulator protein RAMP2 is essential for angiogenesis and vascular integrity. J Clin Invest 2008;118(1):29-39
   PubMed Web of Science ®Google Scholar
• Fernandez-Sauze S, Delfino C, Mabrouk K, Effects of adrenomedullin on endothelial cells in the multistep process of angiogenesis: involvement of CRLR/RAMP2 and CRLR/RAMP3 receptors. Int J Cancer 2004;108(6):797-804
   PubMed Web of Science ®Google Scholar
• Kaafarani I, Fernandez-Sauze S, Berenguer C, Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice. FASEB J 2009;23(10):3424-35
   PubMed Web of Science ®Google Scholar
• Nicoli S, Tobia C, Gualandi L, Calcitonin receptor-like receptor guides arterial differentiation in zebrafish. Blood 2008;111(10):4965-72
   PubMed Web of Science ®Google Scholar
• Yurugi-Kobayashi T, Itoh H, Schroeder T, Adrenomedullin/cyclic AMP pathway induces Notch activation and differentiation of arterial endothelial cells from vascular progenitors. Arterioscler Thromb Vasc Biol 2006;26(9):1977-84
   PubMed Web of Science ®Google Scholar
• Gray GE, Mann RS, Mitsiadis E, Human ligands of the Notch receptor. Am J Pathol 1999;154(3):785-94
   PubMed Web of Science ®Google Scholar
• Shutter JR, Scully S, Fan W, Dll4, a novel Notch ligand expressed in arterial endothelium. Genes Dev 2000;14(11):1313-18
   PubMed Web of Science ®Google Scholar
• Roca C, Adams RH. Regulation of vascular morphogenesis by Notch signaling. Genes Dev 2007;21(20):2511-24
   PubMed Web of Science ®Google Scholar
• Claxton S, Fruttiger M. Periodic Delta-like 4 expression in developing retinal arteries. Gene Expr Patterns 2004;5(1):123-7
   PubMed Web of Science ®Google Scholar
• Favre CJ, Mancuso M, Maas K, Expression of genes involved in vascular development and angiogenesis in endothelial cells of adult lung. Am J Physiol Heart Circ Physiol 2003;285(5):H1917-38
   Web of Science ®Google Scholar
• Hofmann JJ, Iruela-Arispe ML. Notch signaling in blood vessels: who is talking to whom about what? Circ Res 2007;100(11):1556-68
   PubMed Web of Science ®Google Scholar
• Hofmann JJ, Luisa Iruela-Arispe M. Notch expression patterns in the retina: an eye on receptor-ligand distribution during angiogenesis. Gene Expr Patterns 2007;7(4):461-70
   PubMed Web of Science ®Google Scholar
• Villa N, Walker L, Lindsell CE, Vascular expression of Notch pathway receptors and ligands is restricted to arterial vessels. Mech Dev 2001;108(1-2):161-4
   PubMed Web of Science ®Google Scholar
• Hellstrom M, Phng LK, Hofmann JJ, Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007;445(7129):776-80
   PubMed Web of Science ®Google Scholar
• Leslie JD, Ariza-McNaughton L, Bermange AL, Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis. Development 2007;134(5):839-44
   PubMed Web of Science ®Google Scholar
• Suchting S, Freitas C, le Noble F, The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci USA 2007;104(9):3225-30
   PubMed Web of Science ®Google Scholar
• Carlson TR, Yan Y, Wu X, Endothelial expression of constitutively active Notch4 elicits reversible arteriovenous malformations in adult mice. Proc Natl Acad Sci USA 2005;102(28):9884-9
   PubMed Web of Science ®Google Scholar
• Kim YH, Hu H, Guevara-Gallardo S, Artery and vein size is balanced by Notch and ephrin B2/EphB4 during angiogenesis. Development 2008;135(22):3755-64
   PubMed Web of Science ®Google Scholar
• Krebs LT, Shutter JR, Tanigaki K, Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. Genes Dev 2004;18(20):2469-73
   PubMed Web of Science ®Google Scholar
• Trindade A, Kumar SR, Scehnet JS, Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos. Blood 2008;112(5):1720-9
   PubMed Web of Science ®Google Scholar
• Benedito R, Trindade A, Hirashima M, Loss of Notch signalling induced by Dll4 causes arterial calibre reduction by increasing endothelial cell response to angiogenic stimuli. BMC Dev Biol 2008;8:117
   PubMed Web of Science ®Google Scholar
• Hodkinson PS, Elliott PA, Lad Y, Mammalian NOTCH-1 activates beta1 integrins via the small GTPase R-Ras. J Biol Chem 2007;282(39):28991-9001
   PubMed Web of Science ®Google Scholar
• Noguera-Troise I, Daly C, Papadopoulos NJ, Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006;444(7122):1032-7
   PubMed Web of Science ®Google Scholar
• Ridgway J, Zhang G, Wu Y, Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006;444(7122):1083-7
   PubMed Web of Science ®Google Scholar
• Scehnet JS, Jiang W, Kumar SR, Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 2007;109(11):4753-60
   PubMed Web of Science ®Google Scholar
• Kim W, Moon SO, Sung MJ, Angiogenic role of adrenomedullin through activation of Akt, mitogen-activated protein kinase, and focal adhesion kinase in endothelial cells. FASEB J 2003;17(13):1937-9
   PubMedGoogle Scholar
• Shichiri M, Kato H, Doi M, Induction of max by adrenomedullin and calcitonin gene-related peptide antagonizes endothelial apoptosis. Mol Endocrinol 1999;13(8):1353-63
   PubMedGoogle Scholar
• Ouafik L, Berenguer-Daize C, Berthois Y. Adrenomedullin promotes cell cycle transit and up-regulates cyclin D1 protein level in human glioblastoma cells through the activation of c-Jun/JNK/AP-1 signal transduction pathway. Cell Signal 2009;21(4):597-608
   PubMed Web of Science ®Google Scholar
• Albertin G, Sorato E, Oselladore B, Involvement of vascular endothelial growth factor signaling in CLR/RAMP1 and CLR/RAMP2-mediated pro-angiogenic effect of intermedin on human vascular endothelial cells. Int J Mol Med 2010;26(2):289-94
   PubMed Web of Science ®Google Scholar
• Garcia MA, Martin-Santamaria S, de Pascual-Teresa B, Adrenomedullin: a new and promising target for drug discovery. Expert Opin Ther Targets 2006;10(2):303-17
   PubMed Web of Science ®Google Scholar
• Moody TW, Miller MJ, Martinez A, Adrenomedullin binds with high affinity, elevates cyclic AMP, and stimulates c-fos mRNA in C6 glioma cells. Peptides 1997;18(8):1111-15
   PubMed Web of Science ®Google Scholar
• Ramachandran V, Arumugam T, Langley R, The ADMR receptor mediates the effects of adrenomedullin on pancreatic cancer cells and on cells of the tumor microenvironment. PLoS One 2009;4(10):e7502
   Web of Science ®Google Scholar
• Miseki T, Kawakami H, Natsuizaka M, Suppression of tumor growth by intra-muscular transfer of naked DNA encoding adrenomedullin antagonist. Cancer Gene Ther 2007;14(1):39-44
   PubMed Web of Science ®Google Scholar
• Tsuchiya K, Hida K, Hida Y, Adrenomedullin antagonist suppresses tumor formation in renal cell carcinoma through inhibitory effects on tumor endothelial cells and endothelial progenitor mobilization. Int J Oncol 2010;36(6):1379-86
   PubMed Web of Science ®Google Scholar
• Hida K, Hida Y, Amin DN, Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004;64(22):8249-55
   PubMed Web of Science ®Google Scholar
• Hida K, Hida Y, Shindoh M. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci 2008;99(3):459-66
   PubMed Web of Science ®Google Scholar
• Hida K, Klagsbrun M. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res 2005;65(7):2507-10
   PubMed Web of Science ®Google Scholar
• Izzedine H, Rixe O, Billemont B, Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 2007;50(2):203-18
   PubMed Web of Science ®Google Scholar
• Chao J, Chao L. The role of adrenomedullin in cardiovascular and renal function. Drug News Perspect 2002;15(8):511-18
   PubMedGoogle Scholar
• Oba S, Hino M, Fujita T. Adrenomedullin protects against oxidative stress-induced podocyte injury as an endogenous antioxidant. Nephrol Dial Transplant 2008;23(2):510-17
   PubMed Web of Science ®Google Scholar
• Dotsch J, Schoof E, Schocklmann HO, Nitric oxide increases adrenomedullin receptor function in rat mesangial cells. Kidney Int 2002;61(5):1707-13
   PubMed Web of Science ®Google Scholar
• Troughton RW, Lewis LK, Yandle TG, Hemodynamic, hormone, and urinary effects of adrenomedullin infusion in essential hypertension. Hypertension 2000;36(4):588-93
   PubMed Web of Science ®Google Scholar
• Troughton RD, Lainchbury JG, McGregor DO, Adrenomedullin in hypertension. Curr Hypertens Rep 2000;2(1):1-2
   PubMedGoogle Scholar
• Nishimatsu H, Hirata Y, Shindo T, Role of endogenous adrenomedullin in the regulation of vascular tone and ischemic renal injury: studies on transgenic/knockout mice of adrenomedullin gene. Circ Res 2002;90(6):657-63
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8(8):592-603
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358(19):2039-49
   PubMed Web of Science ®Google Scholar
• Okazaki T, Ebihara S, Asada M, Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. Int Immunol 2006;18(1):1-9
   PubMed Web of Science ®Google Scholar
• Erber R, Thurnher A, Katsen AD, Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18(2):338-40
   PubMed Web of Science ®Google Scholar
• Helfrich I, Scheffrahn I, Bartling S, Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 2010;207(3):491-503
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-11
   PubMed Web of Science ®Google Scholar
• Hasselbalch B, Lassen U, Hansen S, Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 2010;12(5):508-16
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28(13):2137-43
   PubMed Web of Science ®Google Scholar
• Bose D, Meric-Bernstam F, Hofstetter W, Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol 2010;11(4):373-82
   PubMed Web of Science ®Google Scholar
• Eng FC, Easson AM, Szentgyorgyi E, Knox JJ. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma. Eur J Surg Oncol 2009;35(2):219-21
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Fehrenbacher L, Cartwright T, Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91(3):173-80
   PubMed Web of Science ®Google Scholar
• Thomas AA, Rini BI, Stephenson AJ, Surgical resection of renal cell carcinoma after targeted therapy. J Urol 2009;182(3):881-6
   PubMed Web of Science ®Google Scholar
• Murakami S, Nagaya N, Itoh T, Adrenomedullin regenerates alveoli and vasculature in elastase-induced pulmonary emphysema in mice. Am J Respir Crit Care Med 2005;172(5):581-9
   PubMed Web of Science ®Google Scholar
• Vadivel A, Abozaid S, van Haaften T, Adrenomedullin promotes lung angiogenesis, alveolar development, and repair. Am J Respir Cell Mol Biol 2010;43(2):152-60
   PubMed Web of Science ®Google Scholar
• Wang H, Tomikawa M, Jones MK, Sequential expression of adrenomedullin and its receptor during gastric ulcer healing in rats. Dig Dis Sci 2000;45(3):591-8
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7(9):987-9
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22(11):2184-91
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Hambleton J, Mass RD, Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23(16):3706-12
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Schulz J, McCleod M, Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23(16):3697-705
   PubMed Web of Science ®Google Scholar
• Jin D, Harada K, Ohnishi S, Adrenomedullin induces lymphangiogenesis and ameliorates secondary lymphoedema. Cardiovasc Res 2008;80(3):339-45
   PubMed Web of Science ®Google Scholar
• Fang C, Miguel MA, Avis I, Non-peptide small molecule regulators of lymphangiogenesis. Lymphat Res Biol 2009;7(4):189-96
   PubMedGoogle Scholar